TX-MOGAS-INDUSTRIES
18.5.2023 05:34:29 CEST | Business Wire | Press release
MOGAS Industries, Inc. (MOGAS) will be celebrating its 50-year anniversary with a commemorative celebration on Thursday, May 18th, 2023. The company officially began at 8:20 p.m. on May 17th, 1973.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230517005845/en/
Matt Mogas (left) and Louis Mogas (right) pose next to a large MOGAS ball valve (Photo: Business Wire)
MOGAS has earned a global reputation as a leading severe service manufacturer for the most extreme industrial applications in power, mining, refining, petrochemical/chemical, oil & gas, and specialty application industries. Significant business units include Severe Service Valves, Systems & Consulting (modules), Surface Technologies (coatings), Service & Reliability.
Louis Mogas formed Mogas Machine Works in 1973 with 16 employees working under 19,000 sq ft of manufacturing space on a couple of acres. Today, privately owned MOGAS Industries employs over 325 people across six countries. Their Houston-based headquarters now has 100,000 sq ft of manufacturing capacity spanning 15 acres. Campus improvements, such as 'Class A' corporate offices, an advanced coating facility, a 3-acre wooded park and numerous facility upgrades attest to MOGAS' success—not only as a significant manufacturer—but also to the Company staying true to its original business philosophy of putting people before profits.
A significant part of MOGAS sales is international, with sales and service centers in China, Australia, Canada, South America, Africa, The Middle East, Europe and India. With representatives and technicians in more than 40 countries, MOGAS is known for partnering with its customers to meet the ever-increasing challenges of severe-service applications.
On the occasion of the company’s 50th anniversary, MOGAS CEO/COO Matt Mogas notes: “I feel incredibly blessed to have worked with so many great employees, representatives, and customers these last 33 years. They have made a meaningful impact on MOGAS Industries and me personally. I feel honored to stand on the shoulders of the great men that came before me at MOGAS, especially Sam Furman, Tommy Bright, Cary Lorenz and of course my father, Louis Mogas, the grand architect, master, creator of our culture, beliefs and vision.”
Serving the community is ingrained in the MOGAS culture. The Company contributes significant resources to many worthy causes and enthusiastically supports their employees’ robust spirit of volunteerism. Charitable contributions to organizations include: Ronald McDonald House, MS150, Camp for All, The Periwinkle Foundation, and business partnerships with local elementary and junior schools. The Company also supports private initiatives for public good, focusing on quality of life.
The entire MOGAS organization is proud of this momentous achievement.
For more information, please contact MOGAS Industries at 281.449.0291 or Email: marketing@mogas.com
About MOGAS Industries, Inc.
MOGAS Industries Inc. is the most trusted severe service technology company, providing world-renowned services and the best severe service, application-specific products for critical applications in power, mining, oil & gas, refining, chemical/petrochemical and specialty industries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005845/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom